| Molecular formula | C258H401N79O78 |
| Molecular weight | 5857 g/mol |
| Registered trials | 45 |
| PubChem CID | 71306396 |
What kisspeptin is
Kisspeptin is a peptide compound (PubChem CID 71306396) that has no FDA-approved label and is not approved for any medical use. It is currently studied only in a research setting, and no brand name, dosing standard, or approved indication exists for it.
Trial footprint
Kisspeptin has 45 registered clinical trials. Among the sample of studies available, one completed phase 3 trial examined age-dependent changes in the responsiveness of the hypothalamic pituitary gonadal axis in men. Other listed studies include a completed trial on molecules associated with pediatric obesity and a recruiting trial on functional proteins in polycystic ovary syndrome. These entries reflect the range of populations and questions researchers are investigating, not established outcomes or approved uses.
FAQ
No. Kisspeptin has no FDA-approved label and is not approved for any medical use. It is currently studied only in research settings.
Registered trials include research on the hypothalamic pituitary gonadal axis in men, molecules associated with pediatric obesity, and functional proteins in polycystic ovary syndrome. These are ongoing or completed research studies, not indications of proven benefit.
There are 45 registered clinical trials involving kisspeptin. This reflects an active area of research interest rather than any approved application.
No. Because kisspeptin has not received regulatory approval, no brand name or approved formulation exists.
No adverse event report data is currently available for kisspeptin in this summary. Any safety profile would need to come from the specific research studies in which it is used.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem ClinicalTrials.gov
Updated 2026-09-19